Shots:
- Novartis has reported P-IV (V-DIFFERENCE) trial results evaluating Leqvio (n=898) vs PBO (n=872), both added to personalized lipid-lowering therapy (LLT), in 1,770 hypercholesterolemia pts not at guideline-recommended LDL-C goals
- Trial showed 85% vs 31% achieved their guideline-recommended LDL-C target after 90 days of treatment, with benefits seen as early as day 30 (81% on target) & consistent across age, sex, & CV risk groups
- Also, Leqvio + LLT decreased muscle-related adverse events by 43%, improved pain-related QoL scores, & reduced LDL-C by ~59% after 360 days, a 35% greater reduction than PBO, with benefits seen as early as 60 days; data presented at ESC’25
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis Reports Topline P-III (VAYHIT2) Trial Finding on Ianalumab Regimen to Treat Primary Immune Thrombocytopenia (ITP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
